Amethyst Healthcare Group (@group_amethyst) header
Amethyst Healthcare Group (@group_amethyst) profile picture

We combine proven expertise in cancer care and latest medical technology to design personalised treatments and deliver integrative cancer care.

Europe
Joined April 2024
Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)Photo by Amethyst Healthcare Group (@group_amethyst)
Across Europe, cancer demand is rising, and with it, the pressure on health systems to deliver timely, high-quality care. Radiotherapy should be part of the solution. It is one of the most clinically effective and cost-efficient treatment modalities available, yet in many markets it remains underutilised - constrained by workforce shortages, infrastructure limitations and reimbursement frameworks that make scaling difficult. This sets the stage for an important conversation at HBI 2026 in Paris next week. As part of the Oncology Community Summit, the session “Accelerating Access and Outcomes: Radiotherapy, Workforce, Infrastructure and Investment” (Tuesday 24 March, 14:00 – 15:55) will bring together leaders from across healthcare, investment and innovation to explore how these challenges can be addressed. If you are attending HBI 2026, we look forward to connecting and continuing the conversation.
26
Colorectal cancer remains one of the most commonly diagnosed cancers in Europe, placing a significant burden on patients, healthcare systems, and society. Advances in screening and treatment have improved outcomes in many countries. However, a concerning trend is emerging: colorectal cancer is increasingly being diagnosed in younger adults. Studies across Europe show that incidence among people under 50 has been rising over the past two decades, with significant increases reported in several countries. These trends reinforce the urgent need to: 🔹 Strengthen awareness of symptoms 🔹 Expand participation in screening programmes 🔹 Advance research into the drivers of early-onset disease 🔹 Ensure access to effective and innovative cancer treatments As demand for cancer treatment grows across Europe, ensuring sufficient radiotherapy capacity and equitable access to modern treatment is essential. We are committed to partnering with healthcare systems to expand radiotherapy capacity, increase access to advanced technologies, and help ensure more patients receive timely, high-quality cancer care.
24
Across Europe, radiotherapy remains one of the most effective cancer treatments available, yet many patients who could benefit from it still do not receive it. Addressing this gap requires more than technology alone. It calls for stronger infrastructure, skilled clinical teams and closer collaboration across the oncology ecosystem. As part of the HBI Oncology Community, Ralph Hefti, CEO of Stingray Healthcare Group, recently spoke with Healthcare Business International (HBI) about how these elements must come together to strengthen access to radiotherapy and support the growing demand for cancer treatment. 🎥 Watch the full interview and register for the HBI event: youtube.com/watch?v=sygQfN4B…
20
Cancer prevention starts with awareness. The newly updated European Code Against Cancer provides 14 evidence-based actions that individuals, communities, and policymakers can take to reduce the risk of cancer. Developed by the International Agency for Research on Cancer (IARC) and supported by the European Commission, the Code translates the latest scientific evidence into practical guidance for everyday life. Research suggests that around 40% of cancer cases could be prevented through behavioural and environmental changes such as avoiding tobacco, maintaining a healthy weight, staying physically active, limiting alcohol consumption, and participating in recommended screening programmes. We recognise that tackling cancer requires not only advanced treatment but also strong focus on prevention, education, and early detection. The European Code Against Cancer is an important step in helping people across Europe better understand how lifestyle and screening can reduce cancer risk. 🔗 Learn more about the European Code Against Cancer: cancer-code-europe.iarc.who.…
20
📅 4 March – International HPV Awareness Day HPV causes several cancers, including cervical and oropharyngeal cancers. The good news: many HPV-related cancers are preventable through vaccination and awareness. Vaccination from age 11 provides strong protection and helps reduce future cancer incidence. Alongside prevention, early detection and effective treatments such as modern radiotherapy remain essential for patients diagnosed with HPV-related cancers. At Amethyst Healthcare, we recognise the importance of the full cancer care pathway — from prevention to advanced treatment. Learn more: Parents & educators 👉 lnkd.in/e_Q3W9a6 Healthcare professionals 👉 lnkd.in/eUck6FzA
24
Low-Dose Rate (LDR) vs High-Dose Rate (HDR) Brachytherapy -  what’s the difference? Brachytherapy is a highly targeted form of radiotherapy, delivering radiation directly inside or next to the tumour — maximising dose to cancer while protecting surrounding healthy tissue. 🔹 Low-Dose Rate (LDR) Continuous radiation delivered over a longer period. Sources may be temporary or permanent (e.g. prostate seed implants) and are commonly used in prostate and some gynaecological cancers. 🔹 High-Dose Rate (HDR) Radiation delivered in short, precisely controlled sessions. The source is temporarily placed and removed after each treatment, and is widely used across gynaecological, prostate, breast and other cancers. Both techniques offer excellent tumour control. The choice depends on tumour characteristics, clinical indication, and individual patient needs — reinforcing the importance of personalised, multidisciplinary care.
21
🇷🇴 Advancing Cancer Care Across Romania With clinics in București, Cluj-Napoca, Timișoara, Alba-Iulia, Piatra Neamț, and Satu-Mare, Amethyst is dedicated to ensuring that cancer patients have access to state-of-the-art radiotherapy services closer to home, reducing the need to travel long distances for advanced treatment. The first European centre opened near Bucharest in September 2012, establishing the foundation for a growing national network built around a clear mission: delivering innovative, technology-driven oncology care supported by clinical excellence. Together, these centres are helping to raise the standard of radiotherapy care across Romania.
33
📖 Featured in RAD Magazine Amethyst Healthcare and Stingray Healthcare featured in the latest issue of RAD Magazine, recognising our combination to create Europe’s largest independent cancer care platform. By bringing together extensive expertise and infrastructure across eight countries, we’re strengthening access to high-quality radiotherapy and cancer care for patients across Europe.
18
Radiotherapy remains one of the most clinically effective and cost-efficient cancer treatments available. Yet across Europe, it continues to face workforce pressures and reimbursement frameworks that do not fully reflect its value. How can providers, innovators and investors work together to unlock its full potential? On 24 March in Paris, the Oncology Community Summit - delivered in partnership by Stingray Healthcare Group and Healthcare Business International (HBI) - will bring leaders from across the oncology ecosystem for an important new dialogue on the future of radiotherapy. This session will also mark the official launch of the HBI Oncology Community, bringing together providers, OEMs, technology leaders and investors to explore how radiotherapy can move from the margins to the mainstream of modern oncology care. Discussions will address sustainable scaling within public reimbursement systems, rising demand, and how AI can reshape efficiency, capacity and long-term growth. We are proud to support initiatives that advance collaboration and drive sustainable, high-quality cancer care across Europe.
15
Strengthening radiotherapy services in Italy Amethyst Radioterapia Italia entered the market in 2022 through a strategic partnership with San Carlo Regional Hospital in Potenza, supporting the full technological and structural renewal of its Radiotherapy department, expanding treatment capacity, reducing waiting times and improving local access to care. Looking ahead, a new oncology radiotherapy centre is under development in Genoa (Sturla district), in collaboration with the Liguria Regional Health System and scheduled to open in summer 2027. Through close collaboration with public healthcare partners, we are committed to delivering sustainable, high-quality radiotherapy services that respond to patient needs. Follow Amethyst Radioterapia Italia for updates and news on our work across Italy: linkedin.com/company/amethys…
1
43
The European Parliament’s renewed commitment to Europe’s Beating Cancer Plan sends a strong signal that cancer must remain a priority in the EU’s next budget cycle (2028–2034). With calls for sustainable funding, national accountability, and investment in prevention, workforce capacity and modern equipment, this Resolution reinforces an essential truth: cancer care is a social investment. At Amethyst Healthcare, we welcome this momentum and remain committed to expanding access to high-quality radiotherapy and oncology services across Europe. Now is the time to turn commitment into measurable progress for patients. #CancerCare #Radiotherapy #Oncology #BeatingCancerPlan #HealthcareInvestment
18
Today is World Cancer Day. Behind every cancer diagnosis is a unique human story. It’s a reminder that cancer care must go beyond treatment alone. Through education and innovation, we support people-centred care that sees the whole person — recognising individuality, listening with empathy, and responding to each patient’s needs with dignity and respect. Tackling cancer means reducing inequalities in access to care and placing patients at the heart of every decision. By working collaboratively and innovating responsibly, we strive to deliver care that reflects the uniqueness of every patient. Today, and every day, we stand #UnitedByUnique in the global effort to reduce the impact of cancer.
23
Behind every radiotherapy treatment is a team of highly skilled clinical professionals working together to support patients through some of the most challenging moments of their lives. Across our European centres, radiation oncologists, radiographers, medical physicists, nurses and support teams combine clinical expertise with compassion to deliver safe, precise and patient-centred care. Advanced technology is a vital part of modern cancer treatment — but it is the people behind it who ensure it is used responsibly, thoughtfully and always in the best interests of each patient. Ahead of World Cancer Day tomorrow, we recognise and thank the clinical teams whose dedication underpins the quality of care delivered at every centre, every day.
20
As we approach World Cancer Day on 4 February, we’re reminded that no two cancer journeys are the same. Every patient is unique. Every experience is different. But one thing should never vary - the quality of care each person receives. Across all Amethyst centres, our teams are united by a shared commitment to people-centred care, ensuring every individual is seen as a person first and supported with the same high standards of compassion, expertise and dignity, wherever they are treated. Because while every journey is unique, everyone deserves the same standard of care. #UnitedbyUnique #WorldCancerDay
27
United through public–private collaboration, shaped by local healthcare systems Meeting the growing demand for cancer care requires close collaboration between public health systems and private partners. Across our European network, we work with public-sector organisations to expand access to advanced radiotherapy in line with national priorities and established care pathways. By combining long-term investment, advanced technology and clinical expertise, we support sustainable, patient-centred cancer care. #UnitedByUnique #PublicPrivatePartnerships
28
With World Cancer Day one week away, we’re reflecting on what drives meaningful progress in cancer care. At Amethyst Healthcare Group, collaboration sits at the heart of everything we do - bringing together expertise, partnerships and a shared commitment to patient-centred care. In the lead-up to 4 February, we’ll be sharing perspectives inspired by this year’s theme, #UnitedByUnique, recognising every individual cancer experience and the collective effort needed to improve outcomes. Together, our shared expertise help shape better cancer care.
1
80
📊 New research published in JAMA Network Open (January 2026) provides important prospective evidence on the safety of combining metastases-directed stereotactic radiotherapy (SRT) with biological cancer therapies. This international, multicentre registry study followed 433 patients receiving SRT alongside immunotherapies, monoclonal antibodies, or targeted agents. The study adds valuable prospective data to an area previously dominated by retrospective evidence, supporting the favourable safety profile of SRT in combined-modality treatment strategies for metastatic and oligometastatic cancer. 📖 Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy — JAMA Network Open, January 2026
36
🎥 The recent webinar on the future of oncology care for the working population is now available to watch on YouTube. Delivered in collaboration with Healthcare Business International (HBI), the session also marked the launch of the HBI Oncology Community, a new initiative bringing leaders across the oncology ecosystem together to strengthen collaboration in cancer care. The discussion explored the growing impact of cancer among working-age adults and the need for closer alignment between care providers, insurers and employers to improve access, outcomes and continuity of care. ▶️ Watch the full conversation: youtube.com/watch?v=FTRiutJa…
45
Our values are built on a clear and simple belief: the highest-quality cancer care is delivered when the patient is at the centre of every decision. Across our European centres, we design personalised and comprehensive cancer care pathways, bringing together clinical expertise with access to complementary therapies where appropriate. Each pathway is shaped around individual patient needs, supporting both effective treatment and overall experience of care. In every country where we operate, we work in close partnership with national health systems. Through this collaboration, we combine specialist oncology expertise, advanced radiotherapy technology and a strong focus on patient experience, recognising that better patient experience is closely linked to improved clinical outcomes. These values guide how we deliver care, every day.
21
Advancing cancer care starts with advancing research. In 2024, the Institut national du cancer supported 241 cancer research projects, representing a total investment of €130.1 million, as part of France’s 2021–2030 Cancer Control Strategy. Amethyst Healthcare Group firmly believe that strong, structured research is essential to improving prevention, diagnosis and treatment, and to delivering increasingly precise and innovative radiotherapy solutions for patients worldwide. 🔗 Scientific Report 2024 – INCa lnkd.in/ePmVtdZY
1
57